Quick answer: No clinical trial has tested ashwagandha specifically in women over 50 as a defined group. The closest real evidence comes from four adjacent sources: a perimenopause trial (women in their mid-40s to mid-50s), a postmenopausal trial (ages 40-55) that found improved bone density at a 500mg dose, general-adult stress trials with no age breakdown, and one 2026 trial in adults 60-85 that included both men and women. None of it is a direct, dedicated answer to "does ashwagandha work for women over 50" — this guide shows exactly how close each piece of evidence actually gets, and where it falls short.
Our guides to ashwagandha for men and for women each had to separate genuine sex-specific trial data from general-population evidence wearing a gendered headline. This post needs a third distinction on top of that: genuine age-specific evidence, versus a marketing age-bracket with no dedicated trial behind it. For "women over 50" specifically, that distinction matters more than usual, because — stated plainly — it isn't a studied category at all.
The Honest Starting Point: "Over 50" Isn't a Studied Category
As the quick answer above states, that search came up empty. What gets marketed under this heading is, in every case we could verify, one of a few other things wearing an age-bracket label: general-adult stress and cortisol trials with no age stratification at all, perimenopause trials centered on women in their mid-40s to mid-50s (a real population, but not the same as "over 50" as most readers picture it), a postmenopausal trial spanning ages 40 to 55, or a single 2026 trial in older adults that isn't restricted to women. NCCIH's own ashwagandha reference page doesn't have a menopause or age-50-plus section at all, which is a useful, if blunt, confirmation that this is a genuine evidence gap rather than an oversight on our part (NCCIH).
That gap is worth naming directly rather than papering over, because "over 50" functions in most competing content as a pure SEO wrapper around evidence collected somewhere else entirely. This guide does the opposite: it shows you exactly which evidence is genuinely adjacent to this life stage, how closely it actually matches, and where the real gaps are — the same evidence-tier approach used throughout our guide to ashwagandha's scientific evidence.
What the Adjacent Evidence Actually Shows
Four categories of real research sit near this question, each relating to it imperfectly in a different way.
Perimenopause trials are the closest thing to age-relevant women's evidence in the ashwagandha research base. A 2021 trial gave 100 women (91 completing) with climacteric symptoms during perimenopause 300mg of ashwagandha twice daily for 8 weeks and found a significant reduction in total menopause-symptom scores, alongside increased estradiol and decreased FSH and LH (Gopal et al., 2021). A newer 2026 trial tested the same dose specifically in 60 women aged 45 to 55 over 56 days and found a highly significant reduction in symptom scores (Vani et al., 2026). We could not independently verify Gopal's exact participant age range from the freely available abstract, but "perimenopause" is itself a meaningful boundary — it describes the transition leading up to a woman's final period, typically in the mid-to-late 40s, which is a different population from a postmenopausal woman in her late 50s, 60s, or beyond.
One trial is genuinely postmenopausal, which is a closer match than perimenopause, even though its age range still starts at 40. A 2025 trial randomized 127 postmenopausal women aged 40 to 55 (123 completing, confirmed postmenopausal by 12 months without a period) across six arms — placebo, two doses of ashwagandha alone (250mg and 500mg, a Sensoril-type extract), two doses of Shatavari alone, and a combined arm — over 24 weeks. In the ashwagandha-only arms, the higher 500mg dose produced a significant improvement in lumbar spine bone density T-score versus placebo, and bone turnover markers moved favorably in a dose-dependent pattern (Pingali et al., 2025) — covered in more depth below.
General-adult stress and cortisol trials are the category most often mislabeled. None of the stress or cortisol research covered in our main benefits guide was stratified by age at all — it's evidence about adults generally, not about older women specifically, however a headline frames it.
One trial is genuinely age-relevant but not women-specific. A 2026 randomized, placebo-controlled trial gave 50 healthy adults aged 60 to 85 — 32 men and 18 women — 300mg of ashwagandha twice daily or placebo for 8 weeks. Quality-of-life scores improved significantly with ashwagandha versus placebo at week 4 and further by week 8, daytime sleepiness scores improved, and physical-fitness test sub-scales all improved, with no adverse events reported in the treatment group (Honnutagi et al., 2026). It's real, recent, peer-reviewed evidence in an age range that actually matches "over 50" — but a majority of its participants were men, so it can't be presented as women's evidence either. It's the best adjacent evidence available on age, not a direct answer to this exact question.
Here's the same evidence laid out side by side:
| Evidence type | Trial | Population | Dose | Duration | Key result |
|---|---|---|---|---|---|
| Perimenopause | Gopal et al., 2021 | 100 women with climacteric symptoms during perimenopause (91 completed) | 300mg twice daily | 8 weeks | Reduced menopause-symptom scores; estradiol up, FSH/LH down |
| Perimenopause | Vani et al., 2026 | 60 women, ages 45-55 | 300mg twice daily | 56 days | Highly significant reduction in symptom scores |
| Postmenopause | Pingali et al., 2025 | 127 postmenopausal women, ages 40-55 (123 completed) | 250mg or 500mg once daily | 24 weeks | 500mg dose improved lumbar spine bone density T-score and bone turnover markers |
| Mixed-sex, older adults | Honnutagi et al., 2026 | 50 adults, ages 60-85 (32 men, 18 women) | 300mg twice daily | 8 weeks | Improved quality-of-life, sleepiness, and physical-fitness scores; no adverse events in the treatment group |
| Unverified preprint | Naik et al., 2024 (medRxiv) | 50 adults with a frailty score of 7 or higher, mixed sex | 300mg twice daily (600mg/day) | 8 weeks | Improved frailty scale, 6-minute walk test, sleep, cognition, and quality of life — not yet peer-reviewed |
Menopause-Adjacent Benefits (Full Guide Linked)
Perimenopause and menopause symptoms are where the most genuine evidence relevant to midlife women exists, and we've given that topic its own full guide rather than duplicating the depth here. In short: real trials found reductions in symptom scores, hot flashes, and mood-related measures, with measurable, though numerically modest, shifts in estradiol, FSH, and LH (Gopal et al., 2021; Vani et al., 2026). For the complete breakdown of what these trials found and how they compare, see our guide to ashwagandha for menopause.
Bone, Muscle, and Healthy Aging: What's Plausible vs. Proven
This is the one section in this guide built on trial data that's actually closer to proof than plausibility, so it's worth walking through the numbers rather than just naming the trial.
In the postmenopausal trial above, the ashwagandha-500mg group showed a significant improvement in lumbar spine bone density T-score compared to placebo over 24 weeks, and bone turnover markers — CTX-1 and RANKL, which signal bone breakdown, and osteoprotegerin, which helps protect against it — moved favorably, with the largest effect at the higher dose (Pingali et al., 2025). That's a real, dose-dependent, ashwagandha-alone result (not mixed in with the trial's separate Shatavari arms) in exactly the population — postmenopausal women — this guide is about. It's a single trial, not yet replicated, so we're not calling it settled; but it's genuinely stronger evidence than most claims made under this keyword. Worth flagging: this same trial's own title also names vascular dysfunction as a studied outcome — relevant given that cardiovascular risk rises after menopause — but its specific vascular findings aren't broken out in this guide, since the bone-density result is what's directly on-topic for this section. Readers specifically interested in the vascular-health data should consult the full trial, linked in our Sources list below.
The elderly trial above adds a second, separate data point: its Senior Fitness Test sub-scales — measures of strength, mobility, and balance — all improved significantly with ashwagandha over 8 weeks (Honnutagi et al., 2026), though again, that trial wasn't women-specific.
One more source is worth mentioning only with a clear caveat attached. A 2024 preprint posted on medRxiv describes a trial of 50 adults with a frailty score of 7 or higher (a mix of men and women), given ashwagandha root extract twice daily for 8 weeks, reporting improvements across a frailty scale, a 6-minute walk test, sleep quality, cognitive testing, and quality of life. We want to be explicit about what that citation actually is: a preprint, not a peer-reviewed publication. We searched specifically for evidence that it has since cleared peer review and could not confirm that it has (Naik et al., 2024 — medRxiv preprint, unverified peer-review status). Until that changes, we're presenting it as an unverified preprint only — worth knowing about, not something to treat as settled evidence the way the Pingali and Honnutagi trials above can be.
Thyroid Considerations for This Age Group
Thyroid conditions become genuinely more common with age, and specifically in women — a nationally representative U.S. survey found the highest prevalence of thyroid disease in adults 60 and older (15.4%), with a higher overall rate in women than men (Zhang et al., 2023). That's a real reason the thyroid nuance covered in our main guides matters more, not less, for this demographic specifically. To recap briefly rather than duplicate: an 8-week randomized, placebo-controlled trial in 50 adults with subclinical hypothyroidism found ashwagandha significantly improved TSH, T3, and T4 levels compared to placebo (Sharma et al., 2018), while separate, real case reports describe thyrotoxicosis developing in people who self-administered ashwagandha — including a 73-year-old woman who developed thyrotoxicosis and a rapid heart rhythm after using ashwagandha in place of her prescribed thyroid medication for two years (Kamal et al., 2022). Neither finding is age-specific — we're not aware of research isolating thyroid effects in women over 50 particularly — but because thyroid disorders are more common at this life stage, the general caution has more real-world relevance here than it would for a younger reader. For the complete picture, see our side effects and medication interactions guides.
A Note on Hormone Replacement Therapy
We looked specifically for a clinical trial studying ashwagandha taken alongside hormone replacement therapy and could not find one. What circulates instead, including in some competitor content, is general caution — the reasonable, standard advice to discuss any supplement with the prescriber managing your HRT — not a specific, evidence-backed interaction finding. We're stating that plainly rather than implying a study exists where one doesn't. If you're on HRT and considering ashwagandha, that conversation with your prescriber is worth having precisely because the specific interaction hasn't been studied, not because one has been and found a problem. Our medication interactions guide covers what has and hasn't been documented for ashwagandha more broadly.
A Note on Hormone-Sensitive Cancer History
This is worth stating plainly because this guide already reports the mechanism: the perimenopause trial above found ashwagandha significantly increased serum estradiol while decreasing FSH and LH (Gopal et al., 2021). Breast cancer incidence rises sharply after age 50, and a meaningful share of readers in this age bracket are living with a history of estrogen-receptor-positive breast cancer or are taking hormone-blocking therapy such as tamoxifen or an aromatase inhibitor. No trial has tested ashwagandha specifically in women with a hormone-sensitive cancer history. Memorial Sloan Kettering Cancer Center's patient-facing herb reference notes ashwagandha's measurable effects on reproductive hormones and advises anyone with a hormone-sensitive cancer to discuss it with their oncology team before use (MSKCC). If that describes you, this is a conversation for your oncologist, not a decision to make from a blog post.
Dosage Considerations
None of the trials discussed above used a different dose specifically because participants were older. The perimenopause and postmenopause trials used 300mg twice daily or 250-500mg once daily depending on the extract, and the elderly trial used the same 300mg-twice-daily pattern common across most of this research base. We have no evidence that a different dose is appropriate for this age group, and we're not going to invent one. For the full dosage and timing picture, including how extract types differ, see our dosage and timing guide.
Frequently Asked Questions (FAQ)
Is ashwagandha safe for women with a history of breast cancer or hormone-sensitive cancer? This hasn't been tested in a dedicated trial. Ashwagandha has been shown to raise estradiol in at least one perimenopause trial (Gopal et al., 2021), so women with a history of hormone-sensitive (estrogen-receptor-positive) breast cancer, or who are taking tamoxifen or an aromatase inhibitor, should discuss ashwagandha with their oncology team before use rather than starting it on their own (MSKCC).
Can ashwagandha be taken with thyroid medication like levothyroxine? This combination hasn't been tested in a dedicated trial. Ashwagandha has been shown to raise thyroid hormone levels in people with subclinical hypothyroidism (Sharma et al., 2018), and separate case reports describe thyrotoxicosis in people who used ashwagandha instead of, or alongside, prescribed thyroid medication — including one case after a woman stopped her thyroid medication and relied on ashwagandha alone for two years (Kamal et al., 2022). Anyone on thyroid medication should talk to their prescriber before adding ashwagandha, and should not substitute it for prescribed treatment.
Is there research on ashwagandha specifically for women over 50? No dedicated clinical trial exists. What's available is perimenopause research centered on women in their mid-40s to mid-50s (Gopal et al., 2021; Vani et al., 2026), a postmenopausal trial in women aged 40-55 (Pingali et al., 2025), general-adult stress trials with no age stratification, and one 2026 trial in adults aged 60-85 that isn't women-specific (Honnutagi et al., 2026).
Can ashwagandha help with osteoporosis after menopause? One 2025 trial in postmenopausal women found that a 500mg daily ashwagandha dose significantly improved lumbar spine bone density T-scores and bone turnover markers over 24 weeks (Pingali et al., 2025). That's a genuinely promising, dose-dependent result, but it comes from a single trial that hasn't yet been replicated, so it shouldn't be treated as a substitute for an osteoporosis diagnosis, DEXA scan, or prescribed bone-density treatment.
Is ashwagandha safe for postmenopausal women? One real trial tested it specifically in postmenopausal women and found no unusual safety signal at 24 weeks (Pingali et al., 2025). Beyond that, the general safety picture applies — thyroid effects, rare liver injury reports, and drug interactions — and thyroid issues specifically become more common at this life stage.
Does ashwagandha interact with hormone replacement therapy? We could not find a dedicated study testing this combination. General caution to discuss it with your prescriber is reasonable, but it isn't backed by a specific interaction trial.
Is ashwagandha a substitute for hormone replacement therapy (HRT) after 50? No. Ashwagandha and HRT work through different mechanisms and haven't been directly compared in a trial. The perimenopause and postmenopause trials show modest symptom and hormone changes with ashwagandha alone; HRT is a prescription treatment with a much larger and more direct evidence base for menopausal symptoms. Ashwagandha should be considered a possible complementary option to discuss with a prescriber, not a replacement for HRT.
Can ashwagandha help with menopause symptoms after 50? The trial evidence for perimenopausal and menopausal symptoms is real, but it comes from women in the menopausal transition rather than women specifically past 50. See our full guide to ashwagandha for menopause for the complete picture.
How long does ashwagandha take to work for women in their 50s and 60s? In the closest adjacent trials, measurable effects showed up as early as 4 weeks and continued strengthening through 8 weeks; the postmenopausal bone-density trial measured its main result at 24 weeks (Pingali et al., 2025). No age-specific timeline has been separately studied.
Does ashwagandha cause weight gain or affect metabolism in menopausal or postmenopausal women? None of the trials in perimenopausal, postmenopausal, or older-adult populations discussed in this guide measured weight or metabolic markers as a primary outcome, so there is no direct evidence either way for this specific population. See our dedicated weight-loss guide for what the broader research says about ashwagandha and weight.
What dosage is recommended for older women? No trial has tested a different dose for this age group specifically beyond what's already used in the adjacent trials discussed above — 300mg twice daily is the most common pattern. See our full dosage guide for the complete picture by extract type.
How we made this guide: Researched, written, and fact-checked by The Wellness Voyage editorial team, with every health claim backed by a citable source — recognised health authorities and peer-reviewed studies are linked throughout and listed in full below. We fact-check and review this article periodically and update it as the evidence changes; the last reviewed and updated date is shown with this article. It is written to inform, not to replace personalised advice from a qualified healthcare professional.
Medical disclaimer: This article is for informational purposes only. Always consult a qualified healthcare provider before making changes to your health routine.
Sources
- National Center for Complementary and Integrative Health (NCCIH). Ashwagandha. https://www.nccih.nih.gov/health/ashwagandha
- Gopal S, Ajgaonkar A, Kanchi P, et al. Effect of an ashwagandha root extract on climacteric symptoms in women during perimenopause: a randomized controlled trial. J Obstet Gynaecol Res, 2021 — PubMed. https://pubmed.ncbi.nlm.nih.gov/34553463/
- Vani I, Muralidhar G, Rao BS. A prospective, randomized, double-blind, placebo-controlled study on efficacy and safety of Ashwagandha root extract for managing menopausal symptoms in women. Front Reprod Health, 2025/2026 — PubMed. https://pubmed.ncbi.nlm.nih.gov/41561822/
- Pingali U, Nutalapati C, Wang Y. Ashwagandha and Shatavari Extracts Dose-Dependently Reduce Menopause Symptoms, Vascular Dysfunction, and Bone Resorption in Postmenopausal Women: A Randomized, Double-Blind, Placebo-Controlled Study. J Menopausal Med, 2025 — PubMed. https://pubmed.ncbi.nlm.nih.gov/40347163/
- Honnutagi R, Ingale A, Naikawdi A. Ashwagandha (Withania somnifera) Root Extract Improves General Health in Elderly Men and Women: A Prospective, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study. Phytother Res, 2026 — PubMed. https://pubmed.ncbi.nlm.nih.gov/41725116/
- Naik KS, Muralidhar G, Rao BS, Wankhade K. An 8-Week Oral Therapy with Ashwagandha (Withania Somnifera) Root Extract (600 mg/day) Improves Frailty and Quality of Life in Elderly: A Prospective, Randomized, Placebo-Controlled, Efficacy and Safety Study. medRxiv, 2024 — preprint, peer-review status not confirmed. https://www.medrxiv.org/content/10.1101/2024.10.15.24315515v1
- Zhang X, Wang X, Hu H, Qu H, Xu Y, Li Q. Prevalence and Trends of Thyroid Disease Among Adults, 1999-2018. Endocr Pract, 2023 — PubMed. https://pubmed.ncbi.nlm.nih.gov/37619827/
- Sharma AK, Basu I, Singh S. Efficacy and Safety of Ashwagandha Root Extract in Subclinical Hypothyroid Patients: A Double-Blind, Randomized Placebo-Controlled Trial. J Altern Complement Med, 2018 — PubMed. https://pubmed.ncbi.nlm.nih.gov/28829155/
- Kamal HI, et al. A Case of Thyrotoxicosis Following Self-Administration of Ashwagandha in Place of Prescribed Thyroid Medication. Cureus, 2022 — PubMed. https://pubmed.ncbi.nlm.nih.gov/35475098/
- Memorial Sloan Kettering Cancer Center. Ashwagandha. https://www.mskcc.org/cancer-care/integrative-medicine/herbs/ashwagandha
All sources accessed 24 July 2026.
Emily Johnson, MSc, RH (AHG)
A registered herbalist who separates real age-specific trial data from marketing age-brackets with no dedicated evidence behind them.
